Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03236246 · ClinicalTrials.gov registry record · Phase 4
KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)
A Phase 4 study, sponsored by Keryx Biopharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 206
- Enrollment target
NCT03236246 is a Phase 4 study that has completed, run by Keryx Biopharmaceuticals. The registered enrollment target is 206 participants.
The verdict
NCT03236246, a Phase 4 study, has completed, sponsored by Keryx Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 206 participants
- Enrollment target
Study Summary
The objectives of this study are to assess the long-term efficacy and safety of different dose regimens of KRX-0502 in the treatment of iron deficiency anemia (IDA) in adult subjects with non-dialysis dependent chronic kidney disease (CKD).
Interventions
- DRUG KRX-0502
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2017-08-15 |
| Est. Completion | 2019-09-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03236246
The ClinicalTrials.gov registry entry for NCT03236246 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Keryx Biopharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KRX-0502 is the first listed.
NCT03236246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03236246 about?
NCT03236246 is a clinical study titled "KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)". The objectives of this study are to assess the long-term efficacy and safety of different dose regimens of KRX-0502 in the treatment of iron deficiency anemia (IDA) in adult subjects with non-dialysis dependent chronic kidney disease (CKD).
What is the current status of trial NCT03236246?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 206 participants. The study started on 2017-08-15. Estimated completion is 2019-09-27.
What interventions are being tested in trial NCT03236246?
The interventions under investigation include: KRX-0502 (DRUG).
Who is sponsoring clinical trial NCT03236246?
This trial is sponsored by Keryx Biopharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.